An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline : Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent
Copyright © 2024 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved..
AIMS: To make recommendations on managing the surveillance of patients with stage I, II, III or resectable IV melanoma who are clinically free of disease following treatment with curative intent.
MATERIALS AND METHODS: This guideline was developed by Ontario Health's (Cancer Care Ontario's) Program in Evidence-Based Care and the Melanoma Disease Site Group (including seven medical oncologists, four surgical oncologists, three dermatologists, one radiation oncologist and one patient representative). The MEDLINE, EMBASE, Cochrane Library, PROSPERO databases and the main relevant guideline websites were searched. Internal and external reviews were conducted, with final approval by the Program in Evidence-Based Care and the Melanoma Disease Site Group. The Grading of Recommendations, Assessment, Development and Evaluation approach was followed, and the Modified Delphi method was used.
RESULTS: Based on the current evidence (eight eligible original study papers and four relevant guidelines) and the clinical opinions of the authors of this guideline, the initial recommendations were made. To reach 75% agreement for each recommendation, the Melanoma Disease Site Group (16 members) voted twice and one recommendation was voted on three times. After a comprehensive internal and external review process (including national and international reviewers), 12 recommendations, three weak recommendations and six qualified statements were ultimately made.
CONCLUSIONS: After a systematic review, a comprehensive internal and external review process and a consensus process, the current guideline has been created. The guideline authors believe that this guideline will help clinicians, patients and policymakers make well-informed healthcare decisions that will guide them in clinical melanoma surveillance and ultimately assist in improving patient outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Clinical oncology (Royal College of Radiologists (Great Britain)) - 36(2024), 4 vom: 11. Apr., Seite 243-253 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rajagopal, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical practice guideline |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clon.2024.01.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368259978 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368259978 | ||
| 003 | DE-627 | ||
| 005 | 20240412232818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clon.2024.01.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM368259978 | ||
| 035 | |a (NLM)38336503 | ||
| 035 | |a (PII)S0936-6555(24)00028-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rajagopal, S |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline |b Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a AIMS: To make recommendations on managing the surveillance of patients with stage I, II, III or resectable IV melanoma who are clinically free of disease following treatment with curative intent | ||
| 520 | |a MATERIALS AND METHODS: This guideline was developed by Ontario Health's (Cancer Care Ontario's) Program in Evidence-Based Care and the Melanoma Disease Site Group (including seven medical oncologists, four surgical oncologists, three dermatologists, one radiation oncologist and one patient representative). The MEDLINE, EMBASE, Cochrane Library, PROSPERO databases and the main relevant guideline websites were searched. Internal and external reviews were conducted, with final approval by the Program in Evidence-Based Care and the Melanoma Disease Site Group. The Grading of Recommendations, Assessment, Development and Evaluation approach was followed, and the Modified Delphi method was used | ||
| 520 | |a RESULTS: Based on the current evidence (eight eligible original study papers and four relevant guidelines) and the clinical opinions of the authors of this guideline, the initial recommendations were made. To reach 75% agreement for each recommendation, the Melanoma Disease Site Group (16 members) voted twice and one recommendation was voted on three times. After a comprehensive internal and external review process (including national and international reviewers), 12 recommendations, three weak recommendations and six qualified statements were ultimately made | ||
| 520 | |a CONCLUSIONS: After a systematic review, a comprehensive internal and external review process and a consensus process, the current guideline has been created. The guideline authors believe that this guideline will help clinicians, patients and policymakers make well-informed healthcare decisions that will guide them in clinical melanoma surveillance and ultimately assist in improving patient outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Clinical practice guideline | |
| 650 | 4 | |a follow-up | |
| 650 | 4 | |a frequency | |
| 650 | 4 | |a imaging | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a surveillance | |
| 700 | 1 | |a Yao, X |e verfasserin |4 aut | |
| 700 | 1 | |a Abadir, W |e verfasserin |4 aut | |
| 700 | 1 | |a Baetz, T D |e verfasserin |4 aut | |
| 700 | 1 | |a Easson, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, G |e verfasserin |4 aut | |
| 700 | 1 | |a McWhirter, E |e verfasserin |4 aut | |
| 700 | 1 | |a Nessim, C |e verfasserin |4 aut | |
| 700 | 1 | |a Rosen, C F |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, A |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, F C |e verfasserin |4 aut | |
| 700 | 1 | |a Petrella, T M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical oncology (Royal College of Radiologists (Great Britain)) |d 1995 |g 36(2024), 4 vom: 11. Apr., Seite 243-253 |w (DE-627)NLM012616885 |x 1433-2981 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g number:4 |g day:11 |g month:04 |g pages:243-253 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clon.2024.01.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |e 4 |b 11 |c 04 |h 243-253 | ||